https://orcid.org/0000-0003-4663-4431
References
- Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463–468. doi:10.1016/S1081-1206(10)63152-3
- Gaur SN, Gupta K, Rajpal S, Singh AB, Rohtagi A. Prevalence of bronchial asthma and allergic rhinitis among urban and rural adult population of Delhi. Indian J Allergy Asthma Immunol. 2006;20:90–97.
- Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India - ARIA Asia- Pacific Workshop report. Asian Pac J Allergy Immunol. 2009;27:71–77.
- Kubavat AH, Pawar P, Mittal R, et al. An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. J Assoc Physicians India. 2011;59:424–428.
- Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global allergy and asthma European network; grading of recommendations assessment, development and evaluation working group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476. doi:10.1016/j.jaci.2010.06.047
- Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2011;127(4):927–934. doi:10.1016/j.jaci.2011.01.037
- Stewart M, Ferguson B, Fromer L. Epidemiology and burden of nasal congestion. Int J Gen Med. 2010;8(3):37–45. doi:10.2147/IJGM.S8077
- Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis.. Clin Exp Allergy. 2017;47(7):856–889. doi:10.1111/cea.12953
- Matreja PS, Gupta V, Kaur J, Singh S. Efficacy of fluticasone and oxymetazoline as the treatment for allergic rhinitis [internet].2012. J Clin Diagn Res. 2019;6(1):85–88.
- Ferguson BJ, Paramaesvaran S, Rubinstein E. A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa. Otolaryngol Head Neck Surg. 2001;125(3):253–260. doi:10.1067/mhn.2001.117717
- Inanh S, Öztürk Ö, Korkmaz M, Tutkun A. The effects of the topical agents of fluticasone propionate, oxymetazoline, and 3% and 0.9% sodium chloride solutions on mucociliary clearance in the therapy of acute bacterial rhinosinusitis in vivo. Laryngoscope. 2002;112:320–325. doi:10.1097/00005537-200202000-00022
- Summary of Product Characteristics. Avamys. GlaxoSmithKline UK; 2018.
- Product information leaflet. Otrivin Oxy. glaxosmithkline consumer private limited, India; 2019.
- Liu W, Zhou L, Zeng Q, Luo R. Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: a randomized controlled trial. Sci Rep. 2017;7:40425. doi:10.1038/srep40425
- Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy. 2013;27(2):102–108. PMID: 23562197. doi:10.2500/ajra.2013.27.3864
- Thongngarm T, Assanasen P, Pradubpongsa P, Tantilipikorn P. The effectiveness of oxymetazoline plus intranasal steroid in the treatment of chronic rhinitis: a randomised controlled trial. Asian Pac J Allergy Immunol. 2016;34(1):30–37. PMID: 26994623. doi:10.12932/AP0649.34.1.2016
- Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182(1):19–24. PMID: 20203244. doi:10.1164/rccm.200911-1701OC